{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:39:16Z","timestamp":1793637556787,"version":"4.5.1"},"reference-count":46,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare autoimmune disease characterised by fluctuating and fatigable muscle weakness. In the randomised, double-blind phase III MycarinG study, one 6-week rozanolixizumab cycle significantly improved MG-specific outcomes versus placebo and was generally well tolerated in patients with generalised MG (gMG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of cyclic rozanolixizumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A pooled analysis of the MycarinG, MG0004 and MG0007 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following MycarinG, eligible patients could enrol in the open-label extension studies MG0004 or MG0007 to receive rozanolixizumab 7 or 10\u2009mg\/kg. In MG0004, patients received chronic weekly treatment for \u2a7d52\u2009weeks. In MG0007, after an initial 6-week treatment cycle, subsequent cycles were based on symptom worsening (investigator\u2019s discretion). Final efficacy data were pooled across MycarinG, MG0004 (first 6\u2009weeks) and MG0007 for patients receiving \u2a7e2 symptom-driven cycles. Efficacy endpoints included change from baseline (CFB) in MG Activities of Daily Living (MG-ADL), MG Composite (MGC) and Quantitative MG (QMG) scores. Safety outcomes were assessed in patients who received \u2a7e1 cycle with a \u2a7d8-week follow-up period across MycarinG and MG0007.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Overall, 188 patients received \u2a7e1 cycle and 129 received \u2a7e2 symptom-driven cycles. Across Cycles 1\u201313, mean (standard deviation) CFB to Day 43 in MG-ADL score ranged from \u22123.2 (3.3 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009113; Cycle 3)) to \u22126.0 (3.9 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200924; Cycle 12)). Consistent improvements in MGC and QMG scores were also observed across repeated cycles. Treatment-emergent adverse events (TEAEs) were experienced by 175\/188 (93.1%) patients; most mild or moderate. Incidence remained stable with repeated cyclic treatment among patients who remained in the study at each cycle. The most common TEAE was headache (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200994\/188 (50.0%)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Repeated rozanolixizumab treatment cycles demonstrated consistent, clinically meaningful improvements in MG-specific outcomes as early as 1\u2009week after the first infusion. Rozanolixizumab was generally well tolerated with an acceptable safety profile, supporting its long-term use as a treatment option for adults with gMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT03971422; NCT04124965; NCT04650854.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864261458532","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:12:39Z","timestamp":1782742359000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"first","affiliation":[{"name":"Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University of Toronto, Toronto, ON M5G2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Dru\u017cd\u017c","sequence":"additional","affiliation":[{"name":"Department of Neurology, Municipal Hospital, Poznan\u00b4, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Grosskreutz","sequence":"additional","affiliation":[{"name":"Precision Neurology of Neuromuscular Diseases, Department of Neurology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-9747","authenticated-orcid":false,"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[{"name":"MDA ALS &amp; Neuromuscular Center, Department of Neurology, University of California, Irvine, Orange, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[{"name":"Emeritus and Past Director, Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, Peripheral Nervous System and Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Vu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Boehnlein","sequence":"additional","affiliation":[{"name":"UCB, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Grimson","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Houston","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Kerbusch","sequence":"additional","affiliation":[{"name":"PharmAspire BV, Wijchen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pulido-Valdeolivas","sequence":"additional","affiliation":[{"name":"UCB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00efs","family":"Taranc\u00f3n","sequence":"additional","affiliation":[{"name":"UCB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[{"name":"Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170294"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00660"},{"key":"e_1_3_4_6_2","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith B","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 2018; 10: 1111\u20131130.","journal-title":"MAbs"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00708-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118074"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70436"},{"key":"e_1_3_4_12_2","unstructured":"RYSTIGGO\u00ae US PI https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf (2023 accessed May 2026)."},{"key":"e_1_3_4_13_2","unstructured":"RYSTIGGO\u00ae EU SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rystiggo-epar-product-information_en.pdf (accessed May 2026)."},{"key":"e_1_3_4_14_2","unstructured":"RYSTIGGO\u00ae Japan PI https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/820110_6399432A1028_1_05 (accessed September 2025)."},{"key":"e_1_3_4_15_2","unstructured":"RYSTIGGO\u00ae Canadian Product Monograph https:\/\/pdf.hres.ca\/dpd_pm\/00080069.PDF (2025 accessed May 2026)."},{"key":"e_1_3_4_16_2","unstructured":"RYSTIGGO\u00ae Australian PI https:\/\/www.tga.gov.au\/sites\/default\/files\/2025-08\/auspar-rystiggo-250723-pi.pdf (2025 accessed May 2026)."},{"key":"e_1_3_4_17_2","unstructured":"RYSTIGGO\u00ae Korean PI https:\/\/www.ucbkorea.co.kr\/Rystiggo-inj-Pi.pdf (2025 accessed May 2026)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12958-9"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241305511"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241308181"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23988"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09770-y"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-022-02162-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2025-004655"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28328"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.06.010"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02064-0"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1368525"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730020-00001"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70158"},{"key":"e_1_3_4_37_2","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu L-N","year":"2023","unstructured":"Zhu L-N, Hou H-M, Wang S, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res 2023; 18: 1637\u20131644.","journal-title":"Neural Regen Res"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2312718"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi052628y"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00876-6"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0507-x"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13420-6"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-024-00783-w"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241"},{"key":"e_1_3_4_46_2","unstructured":"Diagnostik und therapie myasthener syndrome https:\/\/register.awmf.org\/assets\/guidelines\/030-087l_S2k_Diagnostik-Therapie-myasthener-Syndrome_2025-01.pdf (2024 accessed May 2026)."},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251361607"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261458532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261458532","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261458532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:29:14Z","timestamp":1784708954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261458532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["10.1177\/17562864261458532"],"URL":"https:\/\/doi.org\/10.1177\/17562864261458532","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17562864261458532"}}